StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Sunday. The firm set a “sell” rating on the stock.

Other research analysts have also recently issued reports about the stock. Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. D. Boral Capital restated a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research report on Tuesday, December 10th.

VolitionRx Stock Up 16.3 %

VNRX stock opened at $0.68 on Friday. The company has a 50-day simple moving average of $0.67 and a 200 day simple moving average of $0.66. The company has a market capitalization of $62.63 million, a P/E ratio of -1.88 and a beta of 1.17. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.23.

Insider Activity

In related news, CEO Cameron John Reynolds acquired 139,811 shares of the business’s stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was purchased at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the acquisition, the director now owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 358,266 shares of company stock worth $204,212. Corporate insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC grew its holdings in VolitionRx Limited (NYSE:VNRX) by 78.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.